A5065723854- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Gut microbiota and health
- Peptidase Inhibition and Analysis
- Biochemical effects in animals
- Chronic Lymphocytic Leukemia Research
- Muscle metabolism and nutrition
- Legume Nitrogen Fixing Symbiosis
- Gastric Cancer Management and Outcomes
- PI3K/AKT/mTOR signaling in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Advanced Breast Cancer Therapies
- Colorectal and Anal Carcinomas
- Cancer Mechanisms and Therapy
- Pancreatic and Hepatic Oncology Research
- Cancer, Stress, Anesthesia, and Immune Response
- Nutrition and Health Studies
Medical University of Lublin
2015-2025
University of Warsaw
1960-2015
Hospital Universitario Son Espases
2013
The significance of Akkermansia bacteria presence in gut micobiome, mainly mucinifila, is currently being investigated the context supporting therapy and marker for response to immunotherapy cancer patients. It indicated that patients with non-small cell lung (NSCLC) treated immune checkpoint inhibitors (ICIs) respond better treatment if this bacterium present intestine.We performed next-generation sequencing microbiome from first or second line anti-PD-1 (anti-programmed death 1) anti-PD-L1...
The current standard of care (SoC) for patients with extensive-disease small-cell lung cancer (ED-SCLC) is chemo-immunotherapy. efficacy radiotherapy (RT) chest consolidation has been established ED-SCLC who have responded to chemotherapy. There a lack data on incorporating RT as and metastasis-directed therapy ED-SCLC. RISE (Radiotherapy Extensive-Stage Small-Cell Lung Cancer) study aims evaluate the effectiveness different strategies residual lesions receive A total 165 will be recruited,...
The composition of the gut microbiome patients with advanced non-small cell lung cancer is currently considered a factor influencing effectiveness treatment immune checkpoint inhibitors. We aimed to evaluate baseline in before receiving first-line immunotherapy alone or combined chemoimmunotherapy. performed 16S rRNA sequencing based on hypervariable regions. Stool samples were collected from 52 NSCLC treated chemoimmunotherapy treatment. found that Ruminococcaceae family, species Alistipes...
In the CodeBreaK 200 phase III, open-label trial, sotorasib significantly improved efficacy versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) for global health status, physical functioning, dyspnea, and cough favored over docetaxel. Here, we report sotorasib's additional impact on quality of life (QOL).
Introduction: Factors other than PD-L1 (Programmed Death Ligand 1) are being sought as predictors for cancer immuno- or chemoimmunotherapy in ongoing studies and long-term observations. Despite high expression on tumor cells, some patients do not benefit from immunotherapy, while others, without the of this molecule, respond to immunotherapy. Attention has been paid composition gut microbiome a potential predictive factor immunotherapy effectiveness. Materials Methods: Our study enrolled 47...
Abstract Background Topoisomerase 2‐alpha ( TOP2A ) is an enzyme that controls topologic changes in DNA during transcription and replication. ERCC1 takes part repair processes. The purpose of this study was to assess the predictive role particular single nucleotide polymorphisms (SNPs) promoter regions genes non‐small cell lung cancer patients (NSCLC) treated with chemotherapy. Materials methods We enrolled 113 NSCLC first line platinum‐based Effectiveness available for 71 patients. isolated...
Abstract Introduction PD-L1 (Programmed Cell Death Ligand 1) is currently the only recognised marker of response to immunotherapy with anti-PD-1 or anti-PD-L1 antibodies in patients advanced non-small cell lung cancer (NSCLC). However, this not perfect. Soluble (sPD-L1) may be a novel predictor efficacy NSCLC patients. Material and methods We enrolled 120 (median age 68 ± 6.81 years, 70 males 50 females) locally (stage IIIB; 10 patients) IV; 110 NSCLC. expression tumour cells was assessed by...
Introduction Expression of PD-L1 on cancer cells is the only validated predictive factor for immunotherapy in NSCLC (Non-Small Cell Lung Cancer) patients. However, this basis, it difficult to predict occurrence resistance immune checkpoint inhibitors (ICIs). MicroRNAs are widely studied as biomarkers cancers. Our study was designed determine whether microRNAs can be sensitive factors qualification patients first-line or chemoimmunotherapy. Material and methods The two-stage research...
Abstract Chemotherapy is a primary treatment for the metastatic lung cancer patients. To select most effective combination of drugs, we need an efficient way assessing tumor response. Here, showed that differential scanning calorimetry (DSC) analysis blood serum proteins could reveal patient response to treatment. If chemotherapy effective, DSC curve non-small cellular (NSCLC) case similar those healthy individuals. fails, notable changes occur in profile NSCLC patient’s serum. Our...
The circulating tumor cells (CTCs) isolation and characterization has a great potential for non-invasive biopsy. In the present research, surface-enhanced Raman spectroscopy (SERS)-based assay utilizing magnetic nanoparticles solid SERS-active support integrated in external field assisted microfluidic device was designed efficient of CTCs from blood samples. Magnetic nanospheres (Fe2O3) were coated with metal then modified p-mercaptobenzoic acid (p-MBA) which works simultaneously as reporter...
Expression of PD-L1 protein on tumor cells, which is so far the only validated predictive factor for immunotherapy, regulated by epigenetic and genetic factors. Among most important ones that regulate gene expression are microRNAs.The study included 60 patients with NSCLC who underwent first or second line immunotherapy pembrolizumab nivolumab. FFPE materials were collected before start immunotherapy. We examined relative microRNAs (miR-141, miR-200a, miR-200b, miR-200c, miR-429, miR-508-3p,...
The newest method of treatment for patients with NSCLC (non-small cell lung cancer) is immunotherapy directed at the immune checkpoints PD-1 (Programmed Cell Death 1) and PD-L1 Ligand 1). only validated predictor factor efficacy, but it imperfect. Some do not benefit from may develop primary or secondary resistance. This study aimed to assess intestinal resistome composition non-small cancer (NSCLC) treated checkpoint inhibitors in context clinical features potentially new prediction factors...
The use of immunotherapy in treatment non-small cell lung cancer (NSCLC) patients with the
The aim of the study was to assess occurrence and nature immune-related endocrine adverse events (irAEs) among patients with non-small-cell lung cancer (NSCLC) treated nivolumab. Methods: group included 35 (15 women, 20 men, 65.8 ± 7.1 years) NSCLC in stage IIIB (n = 16, 45.7%) IV 19,54.3%) who were Results: Of studied patients, 34.3% 12) developed irAEs (irAE group): 22.9% 8) hyperthyroidism 8.6% 3) hypothyroidism, one case, hypophysitis observed. median onset time 2 months. In thyroid...
Exposure to radon is the second most common factor causing lung cancer in smokers and first among non-smokers. We aimed measure impact of exposure on patients with different histological types advanced cancer. The measurement was performed 102 stage 3B or higher (Poland). There were 78.4% non-small cell carcinoma 21.6% small carcinoma. One month trace detectors order control whether high concentrations (>800 Bq/m3) found homes diagnosed. Results determinations then compared representation...